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The COVID-19 pandemic has raised the 
question of  whether psychiatric patients, es-
pecially those with schizophrenia and oth-
er psychotic disorders, are more suscepti-
ble to SARS-CoV-2 infection. At this point 
in time we have to emphasize that there is 
not enough information, especially scientif-
ic and evidence-based, to answer this ques-
tion. The same is true when considering the 
course of  the disease, and also when consid-
ering psychopharmacotherapy itself  (primar-
ily antipsychotics, but also all other psycho-
pharmaceuticals, that is, mood stabilizers, 
antidepressants, anxiolytics, hypnotics and 
pro-cognitive drugs). In case of  an infec-
tion with a marked clinical presentation that 
has to be treated with most commonly used 
drugs (lopinavir / ritonavir, chloroquine / 
hydroxychloroquine and antibiotics), we pro-
vide available information on their poten-
tial interactions with psychopharmaceuticals 
(Table 1). It should be noted that it is advis-
able to use haloperidol in patients who are 
agitated and/or aggressive (whether suffering 
from schizophrenia or some other psychotic 
disorder or in the case of  delirium in other-
wise non-psychotic patients), also available in 
the parenteral formulation. Benzodiazepines, 
on the other hand, are not recommended to 
the same extent because of  their effects on 
the respiratory centre, especially when the ef-
fect of  COVID-19 on the respiratory system 
is considered.
Below, we provide some general informa-
tion and recommendations for this popula-
tion of  psychiatric patients.
General information
To date, the most common symptoms 
of  COVID-19 are: elevated body tempera-
ture, fever, shortness of  breath, dry cough, 
chest pain or pressure, fatigue, muscle pain, 
and difficulty breathing. However, it is im-
portant to point out that, with respect to the 
potential impact of  COVID-19 infection on 
the course and treatment of  psychotic dis-
orders, there is at present no clear evidence 
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that schizophrenia spectrum disorders may 
be exacerbated or psychopharmacotherapy 
influenced by the infection alone. Be that 
as it may, caution should be exercised in pa-
tients with schizophrenia or other psychotic 
disorders with pulmonary comorbidity (e.g. 
COPD), as it has been reported earlier that 
administration of  antipsychotics (especially 
higher dosages) increases the risk of  acute 
respiratory failure. Similarly, the elderly and 
patients with comorbidities (chronic respira-
tory diseases, but also cardiovascular diseases, 
diabetes and malignancies) have the highest 
risk of  developing a more severe COVID-19 
clinical picture, often warranting respiratory 
support. Taking into account that there is a 
considerable number of  patients with these 
comorbidities in the population of  those 
suffering from schizophrenia and other psy-
chotic disorders, it is urgent to follow the 
recommendations of  the Croatian Institute 
of  Public Health. Particular attention should 
be paid to smokers who are more prone to 
develop severe COVID-19 clinical presenta-
tions. It should be noted that the percentage 
of  smokers among patients with psychotic 
disorders is higher than 75%.
Should patients in remission be advised to 
stay home and not report to the hospital?
Patients in remission should not be re-
quired to attend regular check-ups, but to wait 
for the improvement of  general conditions 
and renewal of  outpatient psychiatric servic-
es. In other words, it is necessary to continue 
to adhere to earlier recommendations, espe-
cially regarding the regular use of  prescribed 
psychopharmacotherapy. Alternatively, it is 
possible to arrange a telephone consultation 
with a psychiatrist. Given the circumstances 
of  the current pandemic, it is desirable to al-
low patients to work in their home environ-
ment, but this depends on the nature of  their 
employment and should be agreed upon after 
consultation with the family doctor and em-
ployer. In any case, patients are advised to en-
sure that they have a satisfactory home sup-
ply of  medicines that they regularly take in 
therapy, in order to ensure the recommended 
measures of  physical distancing.
How to reduce the risk of COVID-19 infection 
in patients with schizophrenia and other 
psychotic disorders?
Given that the vaccine for COVID-19 
has not yet been developed, the main way 
to prevent infection is to reduce exposure 
to the virus and therefore general preventa-
tive measures are recommended, as stated 
on the web pages of  the Croatian Institute 







1) Potential risk factors for COVID-19 in-
fection in patients with schizophrenia 
spectrum disorders:
 − Over 60 years old
 − Patients who visit health facilities more 
often
 − Travels or mass gatherings
 − Smoking
 − Patients with comorbidity of  lung disease, 
diabetes, chronic renal or hepatic disease, 
endocrinological and metabolic disorders, 
malignancies and other diseases that fur-
ther immunocompromise the patient
 − Malnutrition
 − Patients on immunosuppressive / immu-
nomodulatory therapy
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2) Procedures related to diagnostics and 
therapy:
 − According to currently available informa-
tion, the risk of  COVID-19 infection is 
not increased with the regular use of  psy-
chopharmaceuticals (all groups)
 − It is recommended to continue current 
psychopharmacotherapy if  the disease is 
in remission
 − In case of  worsening of  symptoms or sus-
pected relapse, it is necessary to contact 
the family doctor or psychiatrist in charge 
or to use emergency psychiatric services
 − It is recommended to delay elective sur-
gery and elective invasive treatment
3) Procedures in case of  symptoms of  re-
spiratory illness (cough, sneezing, sore 
throat, fever, shortness of  breath):
 − Stay at home (don’t go to work, school, 
other collectives, larger family gatherings 
and public places)
 − If  there is a suspected infection with CO-
VID-19, or if  it cannot be safely ruled out, 
epidemiological services should be con-
sulted and their instructions followed
 − Call your chosen physician (telephone / e-
mail) regarding the possibility of  organiz-
ing an emergency check-up. Avoid going 
to a healthcare facility unless your doctor 
advised you differently
 − In an emergency, call 112 or 113 (new call 
centre for any coronavirus questions)
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